PDF herunterladen
Pharmacopsychiatry 2020; 53(06): 263-271
DOI: 10.1055/a-1207-9851
Original Paper

Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients – Results of the COMPAS Study

Bernhard Kis‡
1   Department of Psychiatry, Psychotherapy and Psychosomatics, St. Elisabeth Hospital Niederwenigern, Contilia Group, Hattingen, Germany
2   Department of Psychiatry and Psychotherapy, University Medical Center, Göttingen, Germany
3   LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
,
Caroline Lücke‡
4   Department of Psychiatry and Psychotherapy – University of Bonn, Bonn, Germany
,
Mona Abdel-Hamid
2   Department of Psychiatry and Psychotherapy, University Medical Center, Göttingen, Germany
3   LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
,
Philipp Heßmann
2   Department of Psychiatry and Psychotherapy, University Medical Center, Göttingen, Germany
,
Erika Graf
5   Institute of Medical Biometry and Statistics, Clinical Trials Unit and Medical Faculty, University Medical Center – University of Freiburg, Freiburg, Germany
,
Mathias Berger
6   Department of Psychiatry and Psychotherapy, Medical Faculty, University Medical Center – University of Freiburg, Freiburg, Germany
,
Swantje Matthies
6   Department of Psychiatry and Psychotherapy, Medical Faculty, University Medical Center – University of Freiburg, Freiburg, Germany
,
Patricia Borel
6   Department of Psychiatry and Psychotherapy, Medical Faculty, University Medical Center – University of Freiburg, Freiburg, Germany
,
Esther Sobanski
7   Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
8   Department of Child and Adolescent Psychiatry and Psychotherapy, University Medicine Mainz, Mainz, Germany
,
Barbara Alm
7   Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
Michael Rösler
9   Institute for Forensic Psychology and Psychiatry, Saarland University Faculty of Medicine, Homburg/Saar, Germany
,
Wolfgang Retz
9   Institute for Forensic Psychology and Psychiatry, Saarland University Faculty of Medicine, Homburg/Saar, Germany
10   Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany
,
Christian Jacob
11   Clinic for Psychiatry and Psychotherapy, Medius Clinic, Kirchheim, Germany
,
Michael Colla
12   Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland
,
Michael Huss
8   Department of Child and Adolescent Psychiatry and Psychotherapy, University Medicine Mainz, Mainz, Germany
,
Thomas Jans
13   University Hospital of Würzburg, Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Würzburg, Germany
,
Ludger Tebartz van Elst‡
6   Department of Psychiatry and Psychotherapy, Medical Faculty, University Medical Center – University of Freiburg, Freiburg, Germany
,
Helge H. O. Müller‡
14   Witten/Herdecke University, Faculty of Health/School of Medicine, Integrative Psychiatry and Psychotherapy, Witten, Germany
,
Alexandra Philipsen‡
4   Department of Psychiatry and Psychotherapy – University of Bonn, Bonn, Germany
› Institutsangaben Funding: The COMPAS trial was funded by the German Federal Ministry of Research and Education (01GV0606) and is part of the German network for the treatment of ADHD in children and adults (ADHD-NET). The trial medication (Medikinet retard, licensed as Medikinet adult, and matching placebo) was provided by MEDICE Arzneimittel Puetter GmbH and Co KG.
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Introduction The Comparison of Methylphenidate and Psychotherapy in adult ADHD Study (COMPAS) was a prospective, randomized multicenter clinical trial, comparing methylphenidate (MPH) with placebo (PLAC) in combination with cognitive behavioral group psychotherapy (GPT) or individual clinical management (CM) over the period of 1 year. Here, we report results on treatment safety.

Methods MPH and PLAC were flexibly dosed. Among 433 randomized patients, adverse events (AEs) were documented and analyzed on an “as received” basis during week 0–52. Electrocardiogram data were recorded at baseline and week 24.

Results Comparing 205 patients who received ≥1 dose of MPH with 209 patients who received PLAC, AEs occurring significantly more frequently in the MPH group were decreased appetite (22 vs. 3.8%), dry mouth (15 vs. 4.8%), palpitations (13 vs. 3.3%), gastrointestinal infection (11 vs. 4.8%), agitation (11 vs. 3.3%), restlessness (10 vs. 2.9%), hyperhidrosis, tachycardia, weight decrease (all 6.3 vs. 1.9%), depressive symptom, influenza (both 4.9 vs. 1.0%), and acute tonsillitis (4.4 vs. 0.5%). Syncope occurred significantly more often in the PLAC group (2.4 vs. 0%). Clinically relevant ECG changes occurred very rarely in both groups. Serious AEs were rare and without a significant group difference. The comparison of 206 patients treated with GPT versus 209 patients who received CM revealed no major differences. Serious AE classified as psychiatric occurred in 5 cases in the CM group and in 1 case in the GPT group.

Conclusion In this so far longest-running clinical trial, methylphenidate treatment was safe and well-tolerated.

Key words

Methylphenidate - Adverse events - Adult attention-deficit/hyperactivity disorder - Psychotherapy - Comparison of Methylphenidate and Psychotherapy in adult ADHD Study (COMPAS)

Supporting Information



Publikationsverlauf

Eingereicht: 12. Dezember 2019
Eingereicht: 13. Mai 2020

Angenommen: 19. Juni 2020

Artikel online veröffentlicht:
05. Oktober 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Philipsen A, Jans T, Graf E. et al. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder a randomized clinical trial. JAMA Psychiat 2015; 72: 1199-1210
    CrossrefPubMedGoogle Scholar
  • 2 Gross V, Lucke C, Graf E. et al. Effectiveness of psychotherapy in adult ADHD: what do patients think? Results of the COMPAS Study. J Atten Disord 2017; DOI: 10.1177/1087054717720718.
    CrossrefPubMedGoogle Scholar
  • 3 Fletcher AP. Spontaneous adverse drug reaction reporting vs. event monitoring: A comparison. J R Soc Med 1991; 84: 341-344
    CrossrefPubMedGoogle Scholar
  • 4 Storebo OJ, Ramstad E, Krogh HB. et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev 2015; DOI: 10.1002/14651858.CD009885.pub2. CD009885
    CrossrefPubMedGoogle Scholar
  • 5 Cunill R, Castells X, Tobias A. et al. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: A meta-analysis and meta-regression in over 9000 patients. Psychopharmacol (Berl) 2016; 233: 187-197
    CrossrefPubMedGoogle Scholar
  • 6 Antel J, Albayrak O, Heusch G. et al. Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: Do we need a SCOUT (trial)?. Eur Arch Psychiatry Clin Neurosci 2015; 265: 233-247
    CrossrefPubMedGoogle Scholar
  • 7 Kovshoff H, Banaschewski T, Buitelaar JK. et al. Reports of perceived adverse events of stimulant medication on cognition, motivation, and mood: Qualitative investigation and the generation of items for the medication and cognition rating scale. J Child Adolesc Psychopharmacol 2016; 26: 537-547
    CrossrefPubMedGoogle Scholar
  • 8 Linden M. How to define, find and classify side effects in psychotherapy: From unwanted events to adverse treatment reactions. Clin Psychol Psychother 2013; 20: 286-296
    CrossrefPubMedGoogle Scholar
  • 9 Scott J, Young AH. Psychotherapies should be assessed for both benefit and harm. Br J Psychiatry 2016; 208: 208-209
    CrossrefPubMedGoogle Scholar
  • 10 Dimidjian S, Hollon SD. How would we know if psychotherapy were harmful?. Am Psychol 2010; 65: 21-33
    CrossrefPubMedGoogle Scholar
  • 11 Schermuly-Haupt M-L, Linden M, Rush AJ. Unwanted events and side effects in cognitive behavior therapy. Cognit Ther Res 2018; 42: 219-229
    CrossrefPubMedGoogle Scholar
  • 12 Hesslinger B, Tebartz van Elst L, Nyberg E. et al. Psychotherapy of attention deficit hyperactivity disorder in adults. Eur Arch Psychiatry Clin. Neuroscience 2002; 252: 177-184
    PubMedGoogle Scholar
  • 13 Hirvikoski T, Waaler E, Alfredsson J. et al. Reduced ADHD symptoms in adults with ADHD after structured skills training group: Results from a randomized controlled trial. Behav Res Ther 2011; 49: 175-185
    CrossrefPubMedGoogle Scholar
  • 14 Philipsen A, Richter H, Peters J. et al. Structured group psychotherapy in adults with attention deficit hyperactivity disorder. J Nerv Ment Dis 2007; 195: 1013-1019
    CrossrefPubMedGoogle Scholar
  • 15 Hesslinger B, Philipsen A, Richter H. Psychotherapie der ADHS im Erwachsenenalter: Ein Arbeitsbuch. Hogrefe Verlag; 2004
    Google Scholar
  • 16 Philipsen A, Graf E, Jans T. et al. A randomized controlled multicenter trial on the multimodal treatment of adult attention-deficit hyperactivity disorder: Enrollment and characteristics of the study sample. Atten Defic Hyperact Disord 2014; 6: 35-47
    CrossrefPubMedGoogle Scholar
  • 17 Philipsen A, Graf E, Tebartz van Elst L. et al. Evaluation of the efficacy and effectiveness of a structured disorder tailored psychotherapy in ADHD in adults: Study protocol of a randomized controlled multicentre trial. Atten Defic Hyperact Disord 2010; 2: 203-212
    CrossrefPubMedGoogle Scholar
  • 18 Yokotsuka M, Aoyama M, Kubota K. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM). Int J Med Inform 2000; 57: 139-153
    CrossrefPubMedGoogle Scholar
  • 19 Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109-117
    CrossrefPubMedGoogle Scholar
  • 20 MedDRA. MedDRA Hierarchy https://www.meddra.org/how-to-use/basics/hierarchy 2019
    PubMed
  • 21 Newcombe RG. Interval estimation for the difference between independent proportions: Comparison of eleven methods. Stat Med 1998; 17: 873-890
    CrossrefPubMedGoogle Scholar
  • 22 The European Agency for the Evaluation of Medicinal Products. Points to consider on multiplicity issues in clinical trials 2002 CPMP/EWP/908/99.
    PubMedGoogle Scholar
  • 23 Wigal SB, Nordbrock E, Adjei AL. et al. Efficacy of methylphenidate hydrochloride extended-release capsules (Aptensio XR) in children and adolescents with attention-deficit/hyperactivity disorder: A phase III, randomized, double-blind study. CNS Drugs 2015; 29: 331-340
    CrossrefPubMedGoogle Scholar
  • 24 Pary R, Scarff JR, Jijakli A. et al. A Review of psychostimulants for adults with depression. Fed Pract 2015; 32: 30S-37S
    PubMedGoogle Scholar
  • 25 Damodaran SE, Erumbala G, Abraham D, Doddamani L. A rare, but serious side effect of methylphenidate. Arch Dis Child. 2012 97. Issue Suppl 2
    PubMedGoogle Scholar
  • 26 Castellani G, Contarini G, Mereu M. et al. Dopamine-mediated immunomodulation affects choroid plexus function. Brain Behav Immun 2019; DOI: 10.1016/j.bbi.2019.06.006.
    CrossrefPubMedGoogle Scholar
  • 27 Catala-Lopez F, Hutton B, Nunez-Beltran A. et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2015; 4: 19
    CrossrefPubMedGoogle Scholar
  • 28 Sobanski E, Dopfner M, Ose C. et al. A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment. Atten Defic Hyperact Disord 2013; 5: 387-395
    CrossrefPubMedGoogle Scholar
  • 29 Pringsheim T, Steeves T. Pharmacological treatment for Attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011; DOI: 10.1002/14651858.CD007990.pub2. CD007990
    CrossrefPubMedGoogle Scholar
  • 30 Schulz E, Fleischhaker C, Hennighausen K. et al. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin (R) LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 2010; 20: 377-385
    CrossrefPubMedGoogle Scholar
  • 31 Cortese S, Adamo N, Del Giovane C. et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry 2018; 5: 727-738
    CrossrefPubMedGoogle Scholar
  • 32 Cortese S, Holtmann M, Banaschewski T. et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 2013; 54: 227-246
    CrossrefPubMedGoogle Scholar